4.7 Review

O-GlcNAc and the cardiovascular system

Journal

PHARMACOLOGY & THERAPEUTICS
Volume 142, Issue 1, Pages 62-71

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.pharmthera.2013.11.005

Keywords

Hexosamine biosynthetic pathway; Ischemia-reperfusion injury; Heart failure; Hypertrophy; Mitochondria

Funding

  1. National Institutes of Health [R01 HL083320, R01 HL094419, P20 GM103492, P01 HL078825]

Ask authors/readers for more resources

The cardiovascular system is capable of robust changes in response to physiologic and pathologic stimuli through intricate signaling mechanisms. The area of metabolism has witnessed a veritable renaissance in the cardiovascular system. In particular, the post-translational beta-O-linkage of N-acetylglucosamine (O-G1cNAc) to cellular proteins represents one such signaling pathway that has been implicated in the pathophysiology of cardiovascular disease. This highly dynamic protein modification may induce functional changes in proteins and regulate key cellular processes including translation, transcription, and cell death. In addition, its potential interplay with phosphorylation provides an additional layer of complexity to post-translational regulation. The hexosamine biosynthetic pathway generally requires glucose to form the nucleotide sugar, UDP-G1cNAc. Accordingly, OGlcNAcylation may be altered in response to nutrient availability and cellular stress. Recent literature supports O-G1cNAcylation as an autoprotective response in models of acute stress (hypoxia, ischemia, oxidative stress). Models of sustained stress, such as pressure overload hypertrophy, and infarct-induced heart failure, may also require protein O-G1cNAcylation as a partial compensatory mechanism. Yet, in models of Type II diabetes, OGlcNAcylation has been implicated in the subsequent development of vascular, and even cardiac, dysfunction. This review will address this apparent paradox and discuss the potential mechanisms of O-G1cNAc-mediated cardioprotection and cardiovascular dysfunction. This discussion will also address potential targets for pharmacologic interventions and the unique considerations related to such targets. (c) 2013 Elsevier Inc All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available